Finvector Vision Therapies has initiated arbitration proceedings against Herantis Pharma’s subsidiary Laurantis Pharma and a number of its former shareholders

Herantis Pharma Plc
Company release 09 Mar 2015 at 12:00 pm
Finvector   Vision  Therapies  has  initiated  arbitration  proceedings  against
Herantis  Pharma's  subsidiary  Laurantis  Pharma  and  a  number  of its former
shareholders
Herantis Pharma Plc
Company release 9 March 2015 at 12:00 noon

Finvector   Vision   Therapies   Ltd  ("Finvector")  has  initiated  arbitration
proceedings  against  Herantis  Pharma  Plc's  ("Herantis") subsidiary Laurantis
Pharma Ltd ("Laurantis") and a number of its former shareholders. Herantis holds
99.0 per  cent  of  the  shares  in  Laurantis.  Based on an alleged breach of a
shareholders' agreement regarding Laurantis, Finvector is seeking from Laurantis
and  a  number  of  its  former  shareholders  damages  in  the  total amount of
approximately 1,000,000 euros including interests and costs.

Herantis  was formed in a combination  of two Finnish drug development companies
on 29 April 2014, when Herantis (then Hermo Pharma Ltd) acquired 99.0 percent of
the   shares  of  Laurantis  in  a  share  exchange  transaction.  According  to
Finvector's  claim, the shareholders'  agreement relating to  Laurantis has been
breached in connection with the acquisition of Laurantis' shares.

As  Herantis  understands  it,  there  has  been  no breach of the shareholders'
agreement  and  the  claim  presented  by  Finvector  is unfounded. The arbitral
tribunal convenes in Finland and the dispute is subject to the law of Finland.

Further information:

Herantis Pharma Plc, Pekka Simula, CEO, telephone: +358 40 7300 445
Company web site: www.herantis.com
Certified Advisor: UB Capital Oy, telephone: +358 9 2538 0225

About Herantis Pharma Plc

Herantis Pharma Plc is a pharmaceutical company specialised in new drug research
and  development. The company  focuses on diseases  with an unmet clinical need.
These  diseases include for  example dry eye  syndrome, Parkinson's disease, and
secondary  lymphedema. We believe our drugs are the first or best in their class
and have the potential to change treatment strategies of diseases. The shares of
Herantis  Pharma Plc are  listed on the  First North Finland  marketplace run by
NASDAQ Helsinki stock exchange.